Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. FDA Warning Letter To Sichuan Pharma Only Tip Of The Iceberg For China State-Owned Company

This article was originally published in PharmAsia News

Executive Summary

WASHINGTON and SHANGHAI - U.S. FDA issued Sichuan Pharmaceutical Co., Ltd. a warning letter Sept. 9 for significant deviations from current good manufacturing practices in the manufacture of active pharmaceutical ingredients. The warning letter adds more woes to the troubled China state-owned enterprise, and the Chengdu government is looking for a basement price to unload the company

You may also be interested in...

U.S. FDA Warning Letters Highlight Increased Scrutiny For Foreign Drug Makers

U.S. FDA issues five warning letters to foreign drug makers for failing to register their products as agency beefs up efforts to ensure international compliance.

U.S. FDA Issues Warning Letters To Chinese Firms As Agency Tightens Foreign Field Inspections Program

The agency requests 16 more inspectors in China in an effort to boost enforcement and training.

U.S. Legislative Response to Heparin Crisis Begins to Take Shape

The broad outlines of the timing and scope of a U.S. legislative response to the global pharmaceutical supply chain crisis are taking shape

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts